PALBOLIEVA 100 mg contains Palbociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by inhibiting CDK4 and CDK6, leading to cell-cycle arrest in the G1 phase and suppression of cancer cell proliferation, particularly in hormone receptor–positive breast cancer.

Palbociclib is indicated for:

1. Hormone Receptor-Positive (HR+), HER2-Negative Advanced or Metastatic Breast Cancer
    – In combination with:
•  Aromatase inhibitors (e.g., letrozole) as initial endocrine therapy
•  Fulvestrant in patients with disease progression after endocrine therapy

Common side effects:

•  Neutropenia

•  Leukopenia

•  Fatigue

•  Nausea

•  Stomatitis

Other side effects:

•  Alopecia (mild)

•  Diarrhea

•  Upper respiratory tract infections

Serious side effects:

•  Severe neutropenia

•  Infections

Regular CBC monitoring (especially neutrophils) is mandatory.

Standard adult dose:

•  125 mg once daily for 21 days, followed by 7 days off (28-day cycle)

100 mg capsules are used for dose reduction in case of toxicity.


NOTE: This medicine should be taken only under a doctor’s supervision.